Centre Amends Drugs Rules, 1945
Why in News?
The Ministry of Health and Family Welfare amended the Drugs Rules, 1945, to bring advanced medical technologies under strict central licensing framework.
Expanded CLAA Framework
- Central Authority: The Centrally License Approving Authority (CLAA) framework has been expanded.
- Joint Regulation: These critical medical products will now be subject to joint supervision by both Central and State licensing authorities.
- Previous Scope: Prior to this amendment, the CLAA primarily covered items like vaccines, large-volume parenterals (IV solutions), and r-DNA-based medicines.
Newly Regulated Categories
- Stem Cell Products: Includes stem cell-derived therapies and cellular regenerative treatments.
- Gene Therapeutics: Covers highly complex gene-editing products and gene-replacement procedures.
- Xenografts: Includes animal tissue-derived products, such as specialized animal heart valves used in cardiology and orthopaedics.
Major Regulatory Impacts
- Patient Safety: Eliminates loose interpretations of regulations to ensure high quality and prevent unauthorized patient exploitation.
- Uniform Standards: Ensures consistency in medical manufacturing, testing, and therapeutic quality across all states in India.
- Boost to Innovation: Sets explicit regulatory guidelines, paving a clearer path for biotech startups to safely innovate and deploy precision medicine.
Download Pdf
